Betul Bolat Kucukzeybek

Betul Bolat Kucukzeybek

Auto-generated profile, based on publicly available information

Betul Bolat Kucukzeybek

Department of Pathology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2024 in Medicine
Verified
Journal Article
Open access
BKBetul Bolat Kucukzeybek
Betul Bolat Kucukzeybek
YDYelda Dere
Yelda Dere
ASAysegul Akder Sari
Aysegul Akder Sari
IOIrfan Ocal
Irfan Ocal
EAEmel Avcu
Emel Avcu
YKYuksel Kucukzeybek
Yuksel Kucukzeybek
The prognostic significance of angiogenesis has been demonstrated in various types of cancer. However, in colorectal cancer (CRC), there are conflicting results regarding the relationship between angiogenesis and clinical-histopathological prognostic factors. Mast cells are immune system cells found in the inflammatory microenvironment; their role in carcinogenesis and prognosis remains unclear although they are considered to cause cancer development and progression. The present study aims to evaluate the prognostic significance of mast cell accumulation and angiogenesis assessed by microvessel density (MVD) in patients with CRC. Patients who underwent curative resection and who were not treated with neoadjuvant chemotherapy were included. The anti-CD34 antibody and anti-CD117 antibody were utilized for the immunohistochemical assessment of MVD and the mast cell count (MCC) in the tissue samples, respectively. The relationship between MCC, MVD, survival and clinical-histopathological prognostic factors were evaluated. A total of 94 patients were enrolled to the study. In a median 49-month follow-up, 65 patients (69.1%) died. The 5-year disease-free survival was 61.1% and 31.3% for the group with CD34 < 18.3% and CD34 > 18.3%, respectively (P = .001). The same groups presented 5-year overall survival rates of 77, 1% and 51, 4%, respectively (P, .012). The MVD was found to be associated with the pathological T stage, lymph node metastasis and distant metastasis (P < .05). Although the MCC was positively correlated with MVD, there was no association between the MCC and clinical-histopathological prognostic factors. MVD-assessed angiogenesis was significantly related to survival and the clinical-histopathological prognostic factors in patients diagnosed with CRC.

15 February 2024 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
TCTugba Cetintepe
Tugba Cetintepe
GOGamze Ozkan
Gamze Ozkan
BKBetul Polat Kucukzeybek
Betul Polat Kucukzeybek
LCLutfi Cetintepe
Lutfi Cetintepe
HÜHatice Demet Kiper Ünal
Hatice Demet Kiper Ünal
KPKadriye Bahriye Payzin
Kadriye Bahriye Payzin

13 December 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
HKHaldun Kar
Haldun Kar
SASultan Deniz Altındağ
Sultan Deniz Altındağ
DEDemet Eti̇t
Demet Eti̇t
SYSeyran Yi̇ğİt
Seyran Yi̇ğİt
NANihan Acar
Nihan Acar
KAKemal Atahan
Kemal Atahan
Paget’s disease (PD) of the breast is a very rare presentation of breast malignancy, accounting for 1%–3% of all primary breast tumors. We aimed to evaluate and compare the clinicopathological features and clinical outcome of PD accompanied by in situ carcinoma and invasive cancer. We used the archive of our pathology laboratory retrospectively for age, sex, history of surgery, histopathological findings, treatment modalities, and follow-up information. We used the Kaplan–Meier method for survival analysis. There were 46 female patients diagnosed with PD. In 39 (84.7%) patients, invasive carcinoma accompanied PD, while 7 (15.3%) patients had ductal carcinoma in situ. The median age at diagnosis was 53.5 years. The median follow-up period was 47 months. Of the 39 invasive carcinoma, 10 (25.6%) died during the follow-up period. Invasive ductal carcinoma group had a mean overall survival of rate of 57.8 ± 6.6 months. According to univariate analysis, only the tumor type was found to impact overall survival (p < 0.001). The current study displayed the tumor type as the only parameter affecting overall survival in the invasive carcinoma group. Although it was not statistically significant, breast cancers accompanied by PD were found to be predominantly advanced stage tumors, high grade, hormone receptor negative, and HER2 positive.

4 October 2024 in Medicine
Verified
Journal Article
Open access
BKBetul Bolat Kucukzeybek
Betul Bolat Kucukzeybek
YKYuksel Kucukzeybek
Yuksel Kucukzeybek
YBYasemin Basbinar
Yasemin Basbinar
HEHulya Ellidokuz
Hulya Ellidokuz
MTMustafa Agah Tekindal
Mustafa Agah Tekindal
MTMustafa Oktay Tarhan
Mustafa Oktay Tarhan
Background: Breast cancer is a heterogeneous condition with variations in histopathological, genomic, and biological characteristics. Although clinicopathological prognostic factors and gene expression profiles are commonly used to guide treatment decisions in patients with breast cancer, there is still a need for new prognostic markers. One potential marker is survivin, a protein belonging to the apoptosis inhibitor family. However, studies examining the relationship between survivin and prognosis in breast cancer have yielded inconsistent results. This study aimed to evaluate the impact of survivin expression on the prognosis of breast cancer patients through a meta-analysis. Methods: Studies evaluating survivin expression were sourced from the PubMed, Embase, and Cochrane databases. We conducted a meta-analysis based on full-text articles that evaluated the relationship between survivin expression and survival by immunochemistry or polymerase chain reaction. The studies were initially divided into 2 groups based on the evaluation of overall survival (OS) and disease-free survival (DFS). Subsequently, each group was further categorized according to the method used to detect survivin expression. Statistical analyses for this study were conducted using Stata and JAMOVI. Results: After screening with keywords, we identified 24 retrospective studies evaluating OS and 15 retrospective studies evaluating DFS, which were included in the analysis. We found that the studies in the meta-analysis were not heterogeneous, and this remained consistent when categorizing the groups by survivin expression detection. Survivin expression was associated with OS (HR 1.23, 95% CI 0.81–1.65) and DFS (HR 0.89, CI 0.42–1.36), indicating poor prognosis. This significant relationship between survivin expression and survival persisted when the studies were categorized by the detection method, either immunohistochemistry or polymerase chain reaction. Conclusion: In this study, we evaluated the prognostic significance of survivin expression in patients with breast cancer through a meta-analysis. These results support the use of survivin expression as a prognostic marker in breast cancer, potentially guiding treatment decisions.

2 January 2023 in Florence Nightingale Journal of Nursing
Verified
Journal Article
Open access
MKMustafa Eray Kılıç
Mustafa Eray Kılıç
SÖSena Özcan
Sena Özcan
GKGöksu Kılıç
Göksu Kılıç
BKBetül Bolat Küçükzeybek
Betül Bolat Küçükzeybek
YAYusuf Atmalar
Yusuf Atmalar
BKBadesu Talia Koç
Badesu Talia Koç
AIM: This study investigated whether breast cancer patients had ever applied for Cancer Early Diagnosis Screening and Training Centers (KETEM). METHOD: This study, conducted from November 2020 to April 2021, adopts a cross-sectional research design and is planned as a survey study. The “Diagnosis Rates with Screening Programs in Breast Cancer Patients” survey was conducted on women over 45 who were diagnosed with breast cancer in the Medical Oncology Clinic of İzmir Katip Çelebi University Atatürk Education and Research Hospital. Further information about the cancer stage was gathered from the Medical Oncology outpatient clinic file records. Data obtained in the study were evaluated using the the Statistical Package for Social Sciences version 26.0 software (IBM Corp.; Armonk, NY, USA), using the number, percentage distribution, arithmetic mean, and chi-square test methods. RESULTS: It has been determined that most patients diagnosed did not receive a diagnosis through screening programs, were not aware of KETEM, and did not apply to KETEM. A positive relationship was found between the level of education and participation in screening programs. It was observed that women who knew about the KETEM’s participated more often in the scans. CONCLUSION: The study discovered a lack of knowledge and inadequacy in screening programs for patients with breast cancer. We believe that it is essential to introduce and disseminate KETEMs so that cancers can be detected early through screening. Cite this article as: Kılıç, M. E., Özcan, S., Kılıç, G., Bolat Küçükzeybek, B., Atmalar, Y., & Koç, B. T. (2023). Diagnosis rates through cancer screening programs in patients with breast carcinoma. Florence Nightingale Journal of Nursing, 31(2), 91-96.

23 October 2018 in Konuralp Tip Dergisi
Verified
Journal Article
Open access
PDF file
BKBetül Bolat Küçükzeybek
Betül Bolat Küçükzeybek
HTHali̇l Taşkaynatan
Hali̇l Taşkaynatan
ASAyşegül AKDER SARI
Ayşegül AKDER SARI
SYSeyran Yi̇ği̇t
Seyran Yi̇ği̇t
GBGülden Balli
Gülden Balli
YKYüksel Küçükzeybek
Yüksel Küçükzeybek
En tr Objective : Ki67 is a nuclear protein that is expressed in all phases of the cell cycle except for G o. It is used as a marker to detect the proliferating cells. It has been shown that Ki-67 labeling index is associated with poor clinical outcome in patients with breast cancer. In this study, we aimed to evaluate the prognostic significance of Ki-67 labeling index in patients with estrogen receptor and progesterone receptor positive, HER-2 negative and axillary lymph node negative breast cancer. Methods : Patients diagnosed with breast cancer during 2006-2014, and who were followed up in the medical oncology clinic were included in the study. Immunohistochemically, nuclear Ki-67 proliferation index was evaluated. The relationship with other clinicopathologic prognostic factors was evaluated. Results: 162 patients were included in the study. In a median 85 (9-132)-months follow-up, local recurrence was detected in 2(1.2%) patients and distant metastasis was detected in 7(4.3%) patients. Eight (4.9%) patients died. Patients were divided into two groups using 20% cut-off value for Ki-67 labelling index, obtained by Roc curve analysis. The 7-year overall survival was 97.1% in the group with Ki-67 labeling index below 20%, while it was 90.9% in the group above the 20% value (p=0.042). Ki-67 labeling index showed positive correlation with tumor histological grade, and pathologic tumor size, and negative correlation with hormone receptors. Conclusion : Proliferation is an important indicator for predicting prognosis and treatment response in breast cancer. Ki-67 labeling index is used to determine prognosis along with other clinicopathological prognostic factors, although there is no standard cut-off value and no standard of assessment and no standard in scoring methodology. Amaç : Ki-67 hücre siklusunda G o fazı dışında eksprese edilen nükleer bir proteindir. Prolifere olan hücreleri gösteren belirteç olarak kullanılmaktadır. Meme kanseri tanılı hastalarda Ki-67 proliferasyon indeksinin kötü klinik sonuçlarla ilişkili olduğu gösterilmiştir. Bu çalışmada östrojen reseptörü ve progesteron reseptörü pozitif, HER-2 negatif, aksiller lenf nodu tutulumu bulunmayan meme kanseri tanılı hastalarda Ki-67 proliferasyon indeksinin prognostik öneminin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem : 2006-2014 yılları arasında tanı konulan ve tıbbi onkoloji kliniğinde izlemi bulunan opere meme kanseri tanılı hastalar çalışmaya dahil edildi. İmmunohistokimyasal olarak nükleer Ki-67 proliferasyon indeksi değerlendirildi. Diğer klinikopatolojik prognostik faktörlerle ilişkisi değerlendirildi. Bulgular: 162 hasta çalışmaya dahil edildi. Medyan 85 (9-132) aylık izlemde 2 (%1.2) hastada lokal nüks, 7 (%4.3) hastada uzak metastaz saptandı. Sekiz (%4.9) hasta vefat etti. Ki-67 proliferasyon indeksine göre Roc curve analizinde elde edilen %20 değerine göre hastalar iki gruba ayırıldı. Ki-67 proliferasyon indeksi %20’nin altında ve üzerinde olan gruplarda 7 yıllık genel sağkalımlar sırasıyla %97.1 ve %90.9 olarak hesaplandı (p0.042). Ki-67 proliferasyon indeksinin tümör histolojik derecesi, patolojik tümör boyutu ile pozitif korelasyon, hormon reseptörleri ile negatif korelasyon gösterdiği saptandı. Sonuç : Proliferasyon meme kanserinde prognoz ve tedavi yanıtını predikte etmek için kullanılan önemli bir göstergedir. Ki-67 proliferasyon indeksi için standart eşik değeri bulunmaması, değerlendirme ve skorlama metodolojisinde standart olmamasına rağmen diğer klinikopatolojik prognostik göstergelerle birlikte prognoz belirlenmesinde kullanılmaktadır.